We have developed a new model for drug manufacturing
rBIO has developed a proprietary manufacturing process and licensing model designed to improve the economics of essential peptide drugs, beginning with insulin.
Our story
rBIO was founded to address a basic problem in medicine: essential drugs remain too expensive and vulnerable to supply instability because manufacturing is complex, concentrated, and difficult to scale efficiently.
The company’s work began with insulin, one of the most widely used peptide drugs in the world. Under the leadership of Dr. Deen Bakthavatsalam, CEO and founder, rBIO is now focused on advancing its proprietary manufacturing process toward commercial-scale readiness and licensing.
Cameron Owen, founder, helped establish rBIO’s original business plan and early development path.
Today, rBIO is preparing its insulin manufacturing process for 1,000L scale-up and process-ready licensing.
Our mission
To transform the manufacturing economics of essential peptide drugs by developing a scalable process that can be licensed to qualified partners, beginning with insulin.
Our approach
rBIO is developing a proprietary manufacturing process and IP platform designed to increase output for insulin and other peptide drugs.
The company’s first objective is to complete process scale-up, become process-ready to license, and support partner-enabled commercialization.
Our goal is to improve how essential peptide drugs are manufactured, starting with insulin.
Leadership
Dr. Deen Bakthavatsalam — CEO & Co-Founder
Shawn Swaney — CFO
Cameron Owen — Co-Founder
Board of directors
Stuart Douglass — Executive Chair
Dr. Judith Shizuru — Director
Diane Owen — Director
Scott Douglass — Director
Dr. Deen Bakthavatsalam — Director